Next Article in Journal
A Ten-Year Retrospective Review of Medical Records of Patients Admitted with Meningitis or Encephalitis at Five Hospitals in the United States Highlights the Potential for Under-Ascertainment of Invasive Meningococcal Disease
Previous Article in Journal
Isolation and Characterization of Globisporangium glomeratum (syn. Pythium glomeratum) from Declining Holm Oak in a Historical Garden
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pathogens
Volume 14
Issue 10
10.3390/pathogens14100961
pathogens-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Genetic Characteristics of Acinetobacter baumannii Isolates Circulating in an Intensive Care Unit of an Infectious Diseases Hospital During the COVID-19 Pandemic

by
Svetlana S. Smirnova
1,*,
Dmitry D. Avdyunin
1,
Marina V. Holmanskikh
2,
Yulia S. Stagilskaya
1,
Nikolai N. Zhuikov
1 and
Tarek M. Itani
1
1
Federal Scientific Research Institute of Viral Infections «Virome» Rospotrebnadzor, Letnyaya Street, 23, 620030 Yekaterinburg, Russia
2
The State Autonomous Healthcare Institution of the Sverdlovsk Region “City Infectious Diseases Hospital”, Sulfatnaya Street, 4, 622005 Nizhny Tagil, Russia
*
Author to whom correspondence should be addressed.
Pathogens 2025, 14(10), 961; https://doi.org/10.3390/pathogens14100961
Submission received: 4 September 2025 / Revised: 17 September 2025 / Accepted: 18 September 2025 / Published: 23 September 2025
Browse Figures
Review Reports Versions Notes

Abstract

During the COVID-19 pandemic, a significant increase in the spread of healthcare-associated infections (HAIs) and antimicrobial resistance (AMR) was observed. Acinetobacter baumannii, particularly carbapenem-resistant strains, poses a serious threat in intensive care units (ICUs). This study aimed to genetically characterize A. baumannii isolates from the ICU of an infectious diseases hospital repurposed for COVID-19 patient treatment. Whole-genome sequencing (WGS) was performed on 56 A. baumannii isolates from patients and environmental surfaces using the Illumina MiSeq platform. Bioinformatic analysis included multi-locus sequence typing (MLST), core-genome MLST (cgMLST), phylogenetic analysis, and in silico detection of antimicrobial resistance genes. Three sequence types (STs) were identified: ST2 (35.7%), ST78 (30.4%), and ST19 (3.5%); while 30.4% of the isolates were non-typeable. Phylogenetic analysis revealed clustering of ST2 with isolates from East Africa, ST78 with European isolates, and ST19 with isolates from Germany and Spain. Resistance genes to eight classes of antimicrobials were detected. All isolates were resistant to aminoglycosides and β-lactams. The blaOXA-23 carbapenemase gene was present in all ST2 isolates. cgMLST analysis (cgST-1746) showed significant heterogeneity among ST2 isolates (24–583 allele differences), indicating microevolution within the hospital. A novel synonymous SNP (T2220G) in the rpoB gene was identified. Environmental sampling highlighted the role of contaminated personal protective equipment (PPE) in transmission, with 47.0% of ST2 and 64.3% of ST78 isolates found on PPE. The study underscores the high resolution of WGS and cgMLST for epidemiological surveillance and confirms the critical role of infection control measures in preventing the spread of multidrug-resistant A. baumannii.

1. Introduction

The increasing threat of epidemic-prone infectious diseases is evident from recurrent global outbreaks of emerging viral infections, the rising incidence of healthcare-associated infections (HAIs), and the spread of antimicrobial-resistant (AMR) microorganisms [1]. The prevention of HAIs remains a pressing issue, requiring new approaches in the context of emerging biological threats. In the Russian Federation, the COVID-19 pandemic necessitated the rapid deployment of infectious disease hospitals with segregated “red” and “green” zones, which often led to disruptions in established HAI prevention protocols [2].
These hospitals created dynamic, closed ecosystems where patients underwent numerous invasive procedures and received antimicrobial treatment, fostering the active circulation of pathogens, their adaptation, and the selection of resistant strains [3]. The spread of HAIs and AMR is a recognized contemporary biological threat, challenging patient safety, healthcare workers, and public health [4,5]. Environmental microorganisms can acquire resistance mechanisms and become clinically significant opportunistic pathogens (OP) upon entering hospital ecosystems [6,7].
Acinetobacter baumannii is a prime example—a ubiquitous environmental bacterium that has evolved into a significant OP in healthcare settings [8,9]. Carbapenem-resistant A. baumannii (CRAB) is a leading cause of nosocomial infections in ICUs [10,11]. The COVID-19 pandemic was associated with numerous hospital outbreaks of A. baumannii, posing a severe threat to patients [12,13].
Transmission routes in healthcare facilities are diverse, including direct contact, contaminated surfaces, medical devices, and notably, aerosols and personal protective equipment (PPE) [14,15]. A. baumannii sequence type 2 (ST2) is a successful, globally distributed clonal lineage associated with outbreaks and multidrug resistance (MDR). Classical MLST, based on seven housekeeping genes, lacks the resolution to track the microevolution of A. baumannii within a hospital [16].
High-throughput sequencing methods are essential for accurate epidemiological diagnostics, enabling high-resolution typing, relatedness assessment, and detection of resistance and virulence determinants [17,18,19]. This study aimed to provide a genetic characterization of A. baumannii isolates from an infectious disease hospital ICU during the COVID-19 pandemic using whole-genome sequencing data.

2. Materials and Methods

2.1. Sampling and Bacterial Isolation

From 2022 to 2023, biological and environmental samples were collected from the Nizhny Tagil’s City Infectious Diseases Hospital (Nizhny Tagil, Russian Federation) for treating COVID-19 patients for the presence of OP. These samples were collected in accordance with a scheme for surface swabs patented by the authors, which was developed for simultaneous assessment of both viral and bacterial contamination [20]. The samples were collected using two sterile cotton swabs moistened with 0.1% peptone water containing neutralizers of disinfecting agents for three days every four hours at 20 sampling points from environmental surfaces grouped into three blocks: PPE of medical workers (the outer surface of the doctor’s/nurse’s/orderly’s PPE suit, the outer surface of the upper pair of medical gloves: doctor/nurse/orderly), patient care environment (the surface of medical manipulation table, the outer surface of the medical syringe dispenser, handrails and adjustment levers on an ICU bed, the outer surface of the ventilator), general hospital sampling points (The outer surface of the suction unit, dispensers for liquid soap and hand sanitizer, ICU door handles, oxygen pipeline valves, ICU electric light switches, clinical doctor’s workspace) (Figure 1). A detailed list of each isolate, including its sample ID and the specific sampling point it was obtained from, is provided in Appendix A Table A1.

2.2. Bacterial Isolation and Cultivation

To isolate Acinetobacter from clinical specimens, sputum samples were used. For environmental surveillance, surface swabs were collected from the hospital environment.
Surface swabs were collected from various objects using sterile cotton swabs moistened with 0.1% peptone water containing neutralizers of disinfecting agents.
Sample collection and processing were performed in accordance with the national methodological guidelines MUK 4.2.2942-11 “Methods for sanitary and bacteriological testing of environmental objects, air, and sterility control in healthcare institutions”, which are effective in the Russian Federation.
To isolate the genus Acinetobacter, the swab fluid was inoculated into tubes containing synthetic ethanol-ammonium medium and incubated at 30 °C for 48 h. After enrichment, samples were streaked onto selective agar and incubated at 30 °C for 24–48 h.
Colonies presumptively identified as Acinetobacter were selected for further analysis. Gram staining was performed to identify Gram-negative rods or coccobacilli, and an oxidase test was conducted. Oxidase-negative, Gram-negative cultures were subcultured onto meat-peptone agar (MPA) to obtain pure cultures for transport.

2.3. DNA Extraction and Whole-Genome Sequencing

DNA extraction was performed using the «RIBO-prep» reagent kit (FBIS CRIE, Moscow, Russia) from 24-h cultures grown on MPA following the manufacturer’s protocol. DNA concentration was assessed using a Qubit 4.0 fluorometer and the HS Qubit™ dsDNA HS (High Sensitivity) Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). Only samples with a DNA concentration higher than 0.5 ng/μL were included in the analysis. Samples preparation for whole-genome sequencing was conducted in accordance with the Illumina DNA Prep Reference Guide (document #1000000025416 v10) and the LMN DNA LP (M) Tagmentation Kit (Illumina, San Diego, CA, USA). Briefly, 30 μL of each DNA extract was fragmented, and tagged using the transposome included in the kit, with unique indices (DNA/RNA UD Indexes Set A, Tagmentation, San Diego, CA, USA), added to each sample (Supplementary Table S1). The tagmentation reaction was incubated at 55 °C for 15 min. Subsequent PCR amplification was performed using the Illumina PCR Master Mix with the following conditions: 68 °C for 3 min; 98 °C for 3 min; [98 °C for 45 s, 62 °C for 30 s, 68 °C for 2 min] for 10 cycles; 65 °C for 1 min. Each library and the final library pool were quantified using a Qubit 4.0 fluorometer. Samples were normalized, pooled, and subjected to paired-end sequencing on an Illumina MiSeq system with a MiSeq V2 cartridge (300 cycles). Sample preparation and sequencing were conducted following the manufacturer’s protocol.

2.4. Bioinformatic Analysis

Sequencing data quality was assessed using FastQC 0.12.0, evaluating read counts, maximum/minimum read lengths, GC content, and ambiguous nucleotide proportions for forward and reverse reads.
De novo genome assembly was performed via scaffolding using SPAdes 3.15.5 [21] on the Galaxy server, based on paired-end reads. A taxonomic analysis of scaffolds was conducted using Galaxy’s FCS GX tool 0.5.5 [22] to confirm species identity and remove contaminants. All isolates were confirmed as A. baumannii.
Assembled A. baumannii sequences were cleaned of residual adapters using NCBI VecScreen: FCS Adaptor 0.5.5 [22] and filtered by scaffold length with Trim.seqs 1.39.5 [23].
Typing was performed via multilocus sequence typing (MLST) and core-genome MLST (cgMLST) using the PubMLST database (https://pubmlst.org/, accessed on 3 June 2025).
Multiple sequence alignment and neighbor-joining (NJ) phylogenetic tree construction were performed in Mauve 2.4.0 [24] using the Progressive Mauve algorithm (default parameters: Full Alignment, Sum-of-pairs LCB scoring, and HOXD matrix). Scaffolds were aligned to the NCBI reference sequence GCF_009035845.1 (https://www.ncbi.nlm.nih.gov/datasets/genome/GCF_009035845.1/, accessed on 10 September 2024).
In silico detection of antimicrobial resistance (AMR) determinants was conducted using ResFinder 4.6.0 [25] (default thresholds: ≥90% identity, ≥60% coverage). Input data consisted of fastq files (paired-end reads).
Genome annotation was performed via the NCBI Prokaryotic Genome Annotation Pipeline 6.8. MLST gene alignment and analysis were conducted in MEGA X 10.2.6 using the MUSCLE algorithm. The whole genome sequences obtained in this study were submitted to GenBank under accession numbers JBHYBP000000000–JBHYCK000000000, JBITPW000000000–JBITRA000000000.

3. Results

3.1. Isolate Collection and Sequence Types

A total of 56 A. baumannii isolates were obtained and included in this study. These isolates represented the entire A. baumannii population recovered from a large-scale sampling campaign, which included 1,080 environmental and healthcare workers’ PPE swabs and 36 sputum samples. From this collection, a total of 191 bacterial isolates were obtained, with 56 (29.3%) being identified as A. baumannii. MLST analysis successfully typed 39 isolates, revealing ST2 (n = 20, 35.7%), ST78 (n = 17, 30.4%), and ST19 (n = 2, 3.5%). Seventeen isolates (30.4%) were non-typeable (n/d).
ST2 isolates were obtained from patients (15.0%, n = 3) and hospital environmental surfaces (85.0%, n = 17), with the majority from PPE (47.0%) and patient care environment (41.2%). ST78 isolates were also predominantly isolated from the environmental samples (82.3%, n = 14), with most found on PPE (64.3%). Both ST19 isolates were identified in a patient and on PPE.

3.2. Phylogenetic Analysis

Phylogenetic analysis s to the Russian Federation. ST78 isolates showed relatedness to isolates from Greece, Germany, Finland, Denmark, and Belarus. ST19 isolates were similar to isolates from Germany and Spain (Figure 2).
Within the hospital, clear clustering was observed between patient and environmental isolates. For example, a patient isolate (4-II_S19) clustered with isolates from handrails and adjustment levers on an ICU bed, from an orderly’s PPE, and from ICU door handles. Another large cluster included isolates from various surfaces (ventilator, PPE of doctor’s/nurse’s/orderlie’s, and manipulation table), underscoring the role of healthcare workers in transmission.

3.3. Antimicrobial Resistance Determinants

Resistance genes to eight antimicrobial classes were identified: aminoglycosides, β-lactams, macrolides, streptogramin B, amphenicols, rifamycins, antifolates, and tetracyclines.
All STs showed 100% prevalence of resistance genes to aminoglycosides and β-lactams.
  • ST2: Characteristic profile: armA, aph(6)-Id, aph(3′)-Ia, aph(3″)-Ib, blaOXA-23, msr(E), and mph(E). The blaOXA-23 carbapenemase was present in 100% of isolates.
  • ST78: Characteristic profile: armA, blaOXA-72, blaOXA-90, msr(E), and mph(E). blaOXA-23 was absent.
  • ST19: Profile included aph(3′)-VIa, blaOXA-69, blaADC-25, catA1, sul2, and tet(B).
The n/d group’s resistance profile resembled ST2, suggesting possible genetic relatedness or horizontal gene transfer.
When analyzing genetic profiles, isolates were divided into two groups: 1—patients (Appendix A Table A2); 2—environmental surfaces (Appendix A Table A3). Isolates from both groups represented all detected ST (Figure 3). All ST, including the n/d group, showed 100% presence of resistance determinants to aminoglycosides and β-lactams, with presumed MDR (resistance to 4–5 antimicrobial classes) across all groups.

3.4. Virulence Determinants

The in silico analysis revealed a rich repertoire of virulence-associated genes across all studied isolates. The most prevalent functional groups included genes encoding:
  • Efflux pumps:
    o
    ATP binding cassette: macA, tolC, which were nearly ubiquitous (>90% of isolates);
    o
    Multidrug and toxic compound extrusion: abeM (>90% of isolates);
    o
    Major facilitator superfamily: abaF (>90% of isolates);
    o
    Resistance nodulation division: adeA, adeH, adeI, adeJ, adeK, adeN (>90% of isolates);
    o
    Proteobacterial antimicrobial compound efflux: aceI (>90% of isolates);
    o
    Small multidrug resistance: abeS (>90% of isolates);
    o
    Lipopolysaccharide: lpxC (>90% of isolates).
  • Pili:
    o
    Chaperon-usher type I pili: csuAB (>90% of isolates);
    o
    Type IV pili: pilT/pilU (>90% of isolates).
  • Metal ion uptake systems:
    o
    Acinetobactin: basG, basH, basJ, bauB, bauC, bauD, bauE (>90% of isolates);
    o
    mum operon: mumR (>90% of isolates);
    o
    Metal homeostasis regulators: fur (>90% of isolates);
    o
    Zinc uptake system: zigA, znuB, znuC (>90% of isolates).
  • Two-component systems:
    o
    AdeRS;
    o
    BaeSR;
    o
    BfmRS (>90% of isolates);
    o
    LPS modification: pmrB.
  • Secretion system:
    o
    T1SS: hlyD (>90% of isolates);
    o
    T2SS: gspD, gspE, gspG, gspM (>90% of isolates);
    o
    T4SS: traC, traL, traU, traV, traW;
    o
    T5SS: ata;
    o
    T6SS: tssB, tssC, tssD, tssK (>90% of isolates).
  • Miscellaneous:
    o
    Immune evasion: tuf (>90% of isolates);
    o
    biofilm development: recA;
    o
    In vivo survival, killing of host cells: gigA, gigB, gigC, gigD (>90% of isolates);
    o
    Csu Pili expression: cheA, cheY;
    o
    Neutrophil recruitment: paaE (>90% of isolates);
    o
    Killing of host cells: ompR (>90% of isolates);
    o
    Serum resistance, invasion: cipA;
    o
    Serum resistance, in vivo survival: surA1 (>90% of isolates).
A complete overview of the detected virulence genes, grouped by functional category and sequence type, is provided in Supplementary Table S2.

3.5. Microevolution and SNP Analysis

An analysis of classical MLST genes for ST2 revealed complete identity with reference sequences. However, cgMLST analysis assigned most isolates to a common cgST-1746 but revealed significant heterogeneity, with allele mismatches ranging from 24 to 583 (Table 1). Isolate 188-II_S28 had the highest number of mismatches (583) and contained a unique synonymous SNP (T2220G) in the rpoB gene, not previously reported in databases.

4. Discussion

One of the most prevalent nosocomial pathogens in modern healthcare settings is A. baumannii, which can cause urinary tract infections, bacteremia, meningitis, pneumonia, and catheter-associated infections [26,27]. Immunocompromised systems, particularly those with burn injuries or those admitted to the ICU, are at the highest risk of infection. The recent COVID-19 pandemic was associated with an increased incidence of ventilator-associated nosocomial secondary infections, for which A. baumannii served as a primary etiological agent [28,29].
According to the 2019 Global Antimicrobial Resistance and Use Surveillance System (GLASS) report, 132,000 A. baumannii infections directly contributing to patient mortality were resistant to at least one clinically important antibiotic, with 57,700 fatal cases demonstrating carbapenem resistance [30].
The global prevalence of CRAB continues to rise relentlessly, severely limiting treatment options and exacerbating morbidity and mortality rates associated with these infections.
Key mechanisms of carbapenem resistance in A. baumannii include enzymatic inactivation, porin modifications, efflux pump upregulation, and β-lactamase production. Among the four known β-lactamase classes (A–D), classes B and D are primarily responsible for carbapenem resistance.
OXA-type carbapenemases (Class D) represent the most prevalent carbapenemases in A. baumannii, particularly blaOXA-23-like enzymes. These enzymes are typically plasmid-encoded, facilitating horizontal gene transfer and dissemination within bacterial populations, especially in the hospital environment. The blaOXA-23-like carbapenemase was the first OXA-type carbapenemase identified in CRAB and remains the most globally widespread variant [31]. Consequently, it represents a critical target for molecular surveillance, whose integration into HAIs epidemiological monitoring systems is imperative.
In this study, we showed that ST2 is the predominant lineage in the ICU, with isolates from 3 patients and 17 environmental surfaces (8 from PPE, 7 from patient care areas, and 2 from general hospital sampling points). The prevalence of ST2 reflects the evolutionary success of this clonal lineage (CC2), which accounts for most sequenced genomes globally. The characteristic multidrug resistance profile of ST2 lineage, coupled with limited therapeutic options, ensures its continued prevalence in healthcare facilities [32].
A cgMLST analysis revealed a single prevalence cgST-1746 for most isolates. Isolate 104-II_S26 exhibited both cgST-1746 and cgST-11006, while isolate 188-II_S28 (max mismatches = 583) contained a unique rpoB SNP, potentially indicating accelerated evolutionary adaptation. The mismatch distribution showed no temporal correlation with sampling chronology. The observed cgMLST heterogeneity despite conserved cgST is characteristic of long-term hospital-adapted populations and reflects the remarkable genomic plasticity of A. baumannii.
ST78 represented the second most frequently detected ST, with 3 patient isolates and 14 environmental isolates (9 from PPE, 3 from patient care environment, and 2 from hospital sampling points).
ST19 isolates were sporadically detected and did not significantly impact the epidemiological landscape of the COVID-19 ICU.
Beyond antimicrobial resistance mechanisms, A. baumannii pathogenicity is mediated by diverse virulence factors. While all major STs shared this “core” set of virulence genes, future studies on a larger sample size could elucidate potential subtle differences in virulence profiles between sequence types and their correlation with resistance patterns. Nevertheless, the convergence of MDR (e.g., blaOXA-23) with this robust arsenal of virulence factors underscores the threat posed by these strains and their ability to cause difficult-to-treat infections in a critical care setting.
Phylogenetic analysis incorporating isolates from the PubMLST international database revealed clustering patterns associated with specific geographic regions, suggesting potential pathogen introductions.
Within the infectious disease hospital, distinct clustering was observed between isolates from patients, medical workers’ PPE, and patient environment surfaces. For the two predominant lineages (ST2 and ST78), PPE represented the most contaminated sites (47.0% and 64.3% of isolates, respectively), underscoring the critical importance of strict infection control measures and hygiene practices in healthcare facilities to prevent the spread of antibiotic-resistant bacteria.
In silico analysis identified resistance determinants to eight antimicrobial classes in all A. baumannii isolates. Each sequence type exhibited a characteristic resistance profile. All ST2 samples are characterized by a genetic profile of resistance that includes armA, aph(6)-Id, aph(3′)-Ia, aph(3″)-Ib, blaOXA-23, and msrI genes. Meanwhile, all ST78 samples have a genetic profile of resistance that includes the same resistance genes as ST2, as well as blaOXA-72 and blaOXA-90. Separate resistance genes for various AMR classes have been found in ST19 isolates.
Notably, all ST2 isolates carried the blaOXA-23 carbapenemase, confirming their CRAB status, while this determinant was absent in ST78 and ST19 lineages. The results are very similar to results published during the same COVID-19 period in Croatia, where A. baumannii isolates carrying blaOXA-23 carbapenemase were identified in ICU patients and air conditioners [33]. This finding is consistent with reports from another Croatian hospital, where CRAB was isolated from hospital surfaces [34], highlighting the role of the contaminated hospital environment in the persistence and spread of these pathogens. Similar results of an A. baumannii producing blaOXA-23 carbapenemase outbreak in Basel, Switzerland, were reported in an ICU [35].
One study reported an increased incidence of ventilator-associated pneumonia caused by A. baumannii during the pandemic in Mexico. An increase in resistance to aminoglycosides, carbapenems, folate inhibitors, and other antibiotics was also observed [36]. Furthermore, the detection of genetic determinants of resistance to these antibiotic classes in our samples is consistent with the observed phenotype of multidrug resistance in A. baumannii strains described during the pandemic period.
WGS and cgMLST emerged as the most informative bioinformatics tools, offering superior resolution for HAIs epidemiological surveillance compared to classical MLST approaches.
This study has several limitations. It is restricted to a single ICU, and our conclusions are based solely on genotypic predictions of antimicrobial resistance and virulence, lacking phenotypic validation through standard microbiological methods. Furthermore, while significant genetic heterogeneity was observed, the study design did not allow for the investigation of specific drivers of microevolution, such as detailed patient antibiotic exposure or environmental factors. Despite these limitations, the obtained results emphasize the significance of high-throughput sequencing for studying pathogen biology. By determining the degree of similarity among isolated strains, identifying their resistance and virulence determinants, and investigating the epidemiological connections between pathogens, we can more accurately identify the key factors contributing to nosocomial infections. These findings will be valuable for developing more efficient strategies to prevent and control infections caused by A. baumannii in hospital settings.

5. Conclusions

In conclusion, the ICU environment during the COVID-19 pandemic was dominated by MDR A. baumannii ST2, harboring the armA 16S rRNA methylstransferase and the blaOXA-23 carbapenemase. The study demonstrates the critical role of contaminated environmental surfaces, especially PPE, in the transmission chain. The high resolution of WGS and cgMLST is essential for effective epidemiological surveillance and outbreak investigation. These findings emphasize the need for reinforced infection prevention and control measures in healthcare settings managing vulnerable patient populations.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pathogens14100961/s1, Table S1: Specific dual index combinations; Table S2: Genetic determinants profiles of virulence.

Author Contributions

Conceptualization, S.S.S. and N.N.Z.; methodology, S.S.S., D.D.A. and T.M.I.; software, D.D.A.; validation, Y.S.S. and N.N.Z.; formal analysis, D.D.A.; investigation, S.S.S., Y.S.S., N.N.Z. and T.M.I.; resources, M.V.H.; data curation, D.D.A.; writing—original draft preparation, D.D.A. and S.S.S.; writing—review and editing, all authors; visualization, D.D.A.; supervision, S.S.S.; project administration, S.S.S.; funding acquisition, S.S.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Russian scientific project “Study of the epidemic process and prevention of viral healthcare-associated infections”, Reg. No. 121040500099-5.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki and approved by the Local Ethics Committee of the State Scientific Center of Virology and Biotechnology “Vector” (protocol code N° 3, date of approval 24 June 2022).

Informed Consent Statement

Patient consent was waived due to the retrospective nature of the study and the use of anonymized bacterial isolates obtained as part of routine clinical microbiological surveillance.

Data Availability Statement

The raw sequencing data generated in this study have been deposited in the NCBI SRA database under BioProject accession number PRJNA1165946.

Acknowledgments

The authors thank the staff of the Nizhny Tagil City Infectious Diseases Hospital for their assistance in sample collection.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

AMRAntimicrobial resistance
CRABCarbapenem-resistant A. baumannii
cgMLSTCore-genome MLST
ICUsIntensive care units
HAIsHealthcare-associated infections
OPOpportunistic pathogen
MLSTMulti-locus sequence typing
PPEPersonal protective equipment
STSequence type
WGSWhole-genome sequencing
PCEPatient care environment
GHPGeneral hospital point
AMIAminoglicoside
BLBeta-lactam
MKLMacrolide
SGBStreptogramin b
APAmphenicol
RFRifamycin
AFAntifolates
TETTetracycline

Appendix A

Table A1. Sampling points.
Table A1. Sampling points.
Sample IDSelection GroupSelection Point
5-2-III_S1PPEThe outer surface of the upper pair of medical gloves (orderly)
6-2-III_S35PPEThe outer surface of the orderly’s PPE suit
7-II_S40PCEThe surface of medical manipulation table
13-2-II_S41PCEThe outer surface of the medical syringe dispenser
21-II_S42PPEThe outer surface of the upper pair of medical gloves (doctor)
22-II_S43PPEThe outer surface of the upper pair of medical gloves (nurse)
25-II_S45PPEThe outer surface of the orderly’s PPE suit
26-II_S36PPEThe outer surface of the doctor’s PPE suit
26-III_S22PPEThe outer surface of the orderly’s PPE suit
27-III_S34PCEThe surface of medical manipulation table
28-II_S46PCEHandrails and adjustment levers on an ICU bed
33-II_S47PCEThe outer surface of the medical syringe dispenser
38-II_S48GHPICU door handles
42-III_S7PPEThe outer surface of the doctor’s PPE suit
44-2-III_S6PPEThe outer surface of the nurse’s PPE suit
48-2-III_S4PCEHandrails and adjustment levers on an ICU bed
48-II_S49PCEThe surface of medical manipulation table
49-II_S50PCEHandrails and adjustment levers on an ICU bed
50-2-III_S11PCEThe outer surface of the ventilator
51-II_S51PCEThe outer surface of the ventilator
53-II_S27PCEHandrails and adjustment levers on an ICU bed
55-II_S52PCEThe outer surface of the ventilator
61-II_S53PPEThe outer surface of the upper pair of medical gloves (orderly)
63-II_S54PPEThe outer surface of the upper pair of medical gloves (nurse)
64-II_S55PPEThe outer surface of the nurse’s PPE suit
66-II_S56PPEThe outer surface of the doctor’s PPE suit
69-II_S57PCEHandrails and adjustment levers on an ICU bed
72-III_S10PCEHandrails and adjustment levers on an ICU bed
87-II_S58PCEThe surface of medical manipulation table
89-II_S59PCEHandrails and adjustment levers on an ICU bed
96-II_S23GHPThe outer surface of the suction unit
100-II_S24GHPDispensers for liquid soap and hand sanitizer
102-II_S25PPEThe outer surface of the nurse’s PPE suit
104-II_S26PPEThe outer surface of the orderly’s PPE suit
108-2-III_S9PCEHandrails and adjustment levers on an ICU bed
188-II_S28PCEHandrails and adjustment levers on an ICU bed
198-II_S29GHPICU door handles
221-II_S30PPEThe outer surface of the upper pair of medical gloves (doctor)
284-2-III_S18PPEThe outer surface of the nurse’s PPE suit
285-III_S17PPEThe outer surface of the upper pair of medical gloves (orderly)
286-III_S15PPEThe outer surface of the orderly’s PPE suit
306-III_S14PPEThe outer surface of the orderly’s PPE suit
307-1-II_S32PCEThe surface of medical manipulation table
331-II_S12PCEThe surface of medical manipulation table
344-III_S20PPEThe outer surface of the nurse’s PPE suit
346-II_S33PPEThe outer surface of the orderly’s PPE suit
224-2_S15PPEThe outer surface of the doctor’s PPE suit
Notes: PPE—personal protective equipment; PCE—patient care environment; GHP—general hospital point.
Table A2. Genetic determinants profiles of resistance of patient’s A. baumannii isolates.
Table A2. Genetic determinants profiles of resistance of patient’s A. baumannii isolates.
Sample ID MLST AMI BL MKL SGB AP RF AF TET
armAaph(6)-Id (strB) aph(3′)-Iaaph(3′)-VIa aph(3″)-Ibaph(3′)-VIbaadA1aac(6′)-lb3blaOXA-23blaADC-25blaPER-7blaOXA-66blaCTX-M-124blaOXA-72blaOXA-90blaTEM-1DblaCARB-14msr(E) mph(E) catB8cmlA1floRcatA1ARR-2sul1sul2tet(B)
2-II_S37n/d111010101110000001111001110
4-II_S19ST2111010111111000001110001000
6-531-2-III_S5ST2111010111101000001110000010
7-555-III_S3ST78100000000100111001100010000
13-II_S38ST19000100000100000000000010011
14-II_S21n/d111011001000000111100100001
16-II_S39ST78100000000100111001100010000
17-II_S13ST78100000000100011001100000000
19-II_S16ST2111010111101000001111001110
Notes: AMI—aminoglicoside; BL—beta-lactam; MKL—macrolide; SGB—streptogramin b; AP—amphenicol; RF—rifamycin; AF—antifolates; TET—tetracycline; 1—is available; 0—absent.
Table A3. Genetic determinants profiles of resistance of environmental objects’ A. baumannii isolates.
Table A3. Genetic determinants profiles of resistance of environmental objects’ A. baumannii isolates.
Sample ID MLST AMI BL MKL SGB AP RF AF TET
armAaph(6)-Id (strB) aph(3′)-Iaaph(3′)-VIa aph(3″)-Ibaph(3′)-VibaadA1aac(6′)-lb3blaOXA-23blaADC-25blaPER-7blaOXA-66blaCTX-M-124blaOXA-72blaOXA-90blaTEM-1DblaCARB-14msr(E) mph(E) catB8cmlA1floRcatA1ARR-2sul1sul2tet(B)
5-2-III_S1ST2111010111101000001111001110
6-2-III_S35n/d111010111100000001111001110
7-II_S40n/d111010111111000001111001110
13-2-II_S41n/d100000000000111001100010000
21-II_S42n/d000100000101000000000010011
22-II_S43ST78100000000100111001100010000
25-II_S45n/d100000000000111001100010000
26-II_S36ST78100000000100111001100010000
26-III_S22ST2111010111101000001111001110
27-III_S34ST2111010111101000001111001110
28-II_S46n/d111010111110000001111001110
33-II_S47n/d111010111010000001111001110
38-II_S48ST78100000000100111001100010000
42-III_S7ST2111010111101000001111001110
44-2-III_S6ST2111010111100000001111001110
48-2-III_S4n/d111010111000000001111001110
48-II_S49n/d111010011111000001111001010
49-II_S50n/d111010111010000001111001110
50-2-III_S11ST2111010111101000001111001000
51-II_S51n/d111010111010000001111001000
53-II_S27ST78100000000100111001100010000
55-II_S52ST2111010111111000001111001110
61-II_S53ST2111010111111000001111001110
63-II_S54ST2111010111111000001111001110
64-II_S55n/d111010111010000001111001110
66-II_S56ST78100000000100011001100000000
69-II_S57ST2111010111111000001111001110
72-III_S10ST2111010111101000001111001110
87-II_S58ST78100000000100111001100010000
89-II_S59ST78100000000100111001100010000
96-II_S23ST78100000000100111001100010000
100-II_S24ST2111011001101000111100100011
102-II_S25ST19000100000101000000000010011
104-II_S26ST2111010111000000001111001110
108-2-III_S9ST2111010111101000001111001110
188-II_S28ST2111010111010000001111001110
198-II_S29ST2111010111111000001111001110
221-II_S30ST78100000000100111001100010000
284-2-III_S18ST78100000000000111001100010000
285-III_S17ST78100000000100111001100010000
286-III_S15ST78100000000100111001100010000
306-III_S14ST78100000000100111001100010000
307-1-II_S32n/d111011101110000001111001110
331-II_S12n/d100000000100111001100010000
344-III_S20ST78100000000100111001100010000
346-II_S33ST2111010111111000001111001110
224-2_S15n/d100000000000110001100010000
Notes: AMI—aminoglicoside; BL—beta-lactam; MKL—macrolide; SGB—streptogramin b; AP—amphenicol; RF—rifamycin; AF—antifolates; TET—tetracycline; 1—is available; 0—absent.

References

  1. Ivanov, F.V.; Gumilyevsky, B.Y. Microbiological Monitoring of Healthcare-Associated Infections. Mezhdunarodnyj Nauchno-Issledovatel’skij Zhurnal 2023, 138, 210. (In Russian) [Google Scholar] [CrossRef]
  2. Kutyrev, V.V.; Popova, A.Y.; Smolensky, V.Y.; Ezhlova, E.B.; Demina, Y.V.; Safronov, V.A.; Karnaukhov, I.G.; Ivanova, A.V.; Shcherbakova, S.A. Epidemiological Features of the New Coronavirus Infection (COVID-19). Message 2. Probl. Osob. Opasnykh Infektsii 2020, 2, 6–12. (In Russian) [Google Scholar] [CrossRef]
  3. Brusina, E.B.; Zuyeva, L.P.; Kovalishena, O.V.; Stasenko, V.L.; Feldblium, I.V.; Briko, N.I.; Akimkin, V.G. Infections Related To Medical Care: A Modern Prevention Doctrine. Epidemiol. Vakcinoprofilaktika 2018, 17, 4–10. (In Russian) [Google Scholar] [CrossRef]
  4. O’Toole, R.F. The Interface Between COVID-19 and Bacterial Healthcare-Associated Infections. Clin. Microbiol. Infect. 2021, 27, 1772–1776. [Google Scholar] [CrossRef] [PubMed]
  5. Mustapha, M.M.; Srinivasa, V.R.; Griffith, M.P.; Cho, S.-T.; Evans, D.R.; Waggle, K.; Ezeonwuka, C.; Snyder, D.J.; Marsh, J.W.; Harrison, L.H.; et al. Genomic Diversity of Hospital-Acquired Infections Revealed through Prospective Whole-Genome Sequencing-Based Surveillance. mSystems 2022, 7, e0138421. [Google Scholar] [CrossRef] [PubMed]
  6. Larsson, D.G.J.; Flach, C.F. Antibiotic Resistance in the Environment. Nat. Rev. Microbiol. 2022, 20, 257–269. [Google Scholar] [CrossRef]
  7. Weimann, A.; Dinan, A.M.; Ruis, C.; Bernut, A.; Pont, S.; Brown, K.; Ryan, J.; Santos, L.; Ellison, L.; Ukor, E.; et al. Evolution and Host-Specific Adaptation of Pseudomonas aeruginosa. Science 2024, 385, eadi0908. [Google Scholar] [CrossRef]
  8. Wen, H.; Wang, K.; Liu, Y.; Tay, M.; Lauro, F.M.; Huang, H.; Wu, H.; Liang, H.; Ding, Y.; Givskov, M.; et al. Population Dynamics of an Acinetobacter baumannii Clonal Complex during Colonization of Patients. J. Clin. Microbiol. 2014, 52, 3200–3208. [Google Scholar] [CrossRef]
  9. Roca, I.; Espinal, P.; Vila-Farrés, X.; Vila, J. The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace. Front. Microbiol. 2012, 3, 148. [Google Scholar] [CrossRef]
  10. Antunes, L.C.; Visca, P.; Towner, K.J. Acinetobacter baumannii: Evolution of a Global Pathogen. Pathog. Dis. 2014, 71, 292–301. [Google Scholar] [CrossRef]
  11. Abdul-Mutakabbir, J.C.; Griffith, N.C.; Shields, R.K.; Tverdek, F.P.; Escobar, Z.K. Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists. Infect. Dis. Ther. 2021, 10, 2177–2202. [Google Scholar] [CrossRef]
  12. Boral, J.; Genç, Z.; Pınarlık, F.; Ekinci, G.; Kuskucu, M.A.; İrKören, P.; Kapmaz, M.; Tekin, S.; Çakar, N.; Şentürk, E.; et al. The Association Between Acinetobacter baumannii Infections and the COVID-19 Pandemic in an Intensive Care Unit. Sci. Rep. 2022, 12, 20808. [Google Scholar] [CrossRef]
  13. Noskov, A.K.; Popova, A.Y.; Vodop’ianov, A.S.; Pisanov, R.V.; Chemisova, O.S.; Pavlovich, N.V.; Demina, Y.V.; Gudueva, E.V.; Kovalev, E.V.; Karpushchenko, G.V.; et al. Molecular Genetic Analysis of Bacterial Pneumonia Pathogens Associated with COVID-19 in Rostov-on-Don Hospitals. Zdorov’e Naselenija I Sreda Obitanija 2021, 29, 64–71. (In Russian) [Google Scholar] [CrossRef]
  14. Fröhlich-Nowoisky, J.; Kampf, C.J.; Weber, B.; Huffman, J.A.; Pöhlker, C.; Andreae, M.O.; Lang-Yona, N.; Burrows, S.M.; Gunthe, S.S.; Elbert, W.; et al. Bioaerosols in the Earth System: Climate, Health, and Ecosystem Interactions. Atmos. Res. 2016, 182, 346–376. [Google Scholar] [CrossRef]
  15. Khan, B.A.; Roy, S.; Tahsin, N.; Baidya, K.; Das, K.C.; Islam, S.; Ahsan, N.; Salam, A. Antibiotic Resistance of Bioaerosols in Particulate Matter from Indoor Environments of the Hospitals in Dhaka Bangladesh. Sci. Rep. 2024, 14, 29884. [Google Scholar] [CrossRef]
  16. Bartual, S.G.; Seifert, H.; Hippler, C.; Luzon, M.A.D.; Wisplinghoff, H.; RodrígUez-Valera, F. Development of a Multilocus Sequence Typing Scheme for Characterization of Clinical Isolates of Acinetobacter baumannii. J. Clin. Microbiol. 2005, 43, 4382–4390. [Google Scholar] [CrossRef] [PubMed]
  17. Park, S.; Ryoo, N. Comparative Analysis of IR-Biotyper, MLST, cgMLST, and WGS for Clustering of Vancomycin-Resistant Enterococcus faecium in a Neonatal Intensive Care Unit. Microbiol. Spectr. 2024, 12, e0411923. [Google Scholar] [CrossRef] [PubMed]
  18. Heneghan, C.J.; Spencer, E.A.; Brassey, J.; Plüddemann, A.; Onakpoya, I.J.; Evans, D.H.; Conly, J.M.; Jefferson, T. SARS-CoV-2 and the Role of Orofecal Transmission: A Systematic Review. F1000Research 2021, 10, 231. [Google Scholar] [CrossRef] [PubMed]
  19. Poslova, L.Y.; Sergeeva, A.V.; Kovalishena, O.V. Assessment of Contamination of the Hospital Environment with Intestinal Viruses in the Framework of Epidemiological Surveillance of Acute Intestinal Infections of Viral Etiology. Epidemiologiya 2018, 4, 42–46. (In Russian) [Google Scholar]
  20. Smirnova, S.S.; Zhuikov, N.N.; Egorov, I.A.; Pushkareva, N.A.; Semenov, A.V. Sampling Scheme of Flushes from Environmental Objects for Simultaneous Assessment of Viral and Bacterial Contamination: No. 2022501675. Russian Federation Industrial Design Patent No. 132971, 5 September 2022. (In Russian). [Google Scholar]
  21. Bankevich, A.; Nurk, S.; Antipov, D.; Gurevich, A.A.; Dvorkin, M.; Kulikov, A.S.; Lesin, V.M.; Nikolenko, S.I.; Pham, S.; Prjibelski, A.D.; et al. SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing. J. Comput. Biol. 2012, 19, 455–477. [Google Scholar] [CrossRef]
  22. Astashyn, A.; Tvedte, E.S.; Sweeney, D.; Sapojnikov, V.; Bouk, N.; Joukov, V.; Mozes, E.; Strope, P.K.; Sylla, P.M.; Wagner, L.; et al. Rapid and Sensitive Detection of Genome Contamination at Scale with FCS-GX. Genome Biol. 2024, 25, 60. [Google Scholar] [CrossRef]
  23. Schloss, P.D.; Westcott, S.L.; Ryabin, T.; Hall, J.R.; Hartmann, M.; Hollister, E.B.; Lesniewski, R.A.; Oakley, B.B.; Parks, D.H.; Robinson, C.J.; et al. Introducing Mothur: Open-Source, Platform-Independent, Community-Supported Software for Describing and Comparing Microbial Communities. Appl. Environ. Microbiol. 2009, 75, 7537–7541. [Google Scholar] [CrossRef]
  24. Darling, A.C.; Mau, B.; Blattner, F.R.; Perna, N.T. Mauve: Multiple Alignment of Conserved Genomic Sequence with Rearrangements. Genome Res. 2004, 14, 1394–1403. [Google Scholar] [CrossRef] [PubMed]
  25. Bortolaia, V.; Kaas, R.S.; Ruppe, E.; Roberts, M.C.; Schwarz, S.; Cattoir, V.; Philippon, A.; Allesoe, R.L.; Rebelo, A.R.; Florensa, A.F.; et al. ResFinder 4.0 for Predictions of Phenotypes from Genotypes. J. Antimicrob. Chemother. 2020, 75, 3491–3500. [Google Scholar] [CrossRef] [PubMed]
  26. Maure, A.; Robino, E.; Van der Henst, C. The Intracellular Life of Acinetobacter baumannii. Trends Microbiol. 2023, 31, 1238–1250. [Google Scholar] [CrossRef] [PubMed]
  27. Manfi Ahmed, S.; Hashim Yaseen, K.; Mohammed Mahmood, M. Immunological Evaluation of Individuals Infected with Acinetobacter baumannii. Arch. Razi Inst. 2022, 77, 1813–1819. [Google Scholar] [CrossRef]
  28. Lescure, F.-X.; Bouadma, L.; Nguyen, D.; Parisey, M.; Wicky, P.-H.; Behillil, S.; Gaymard, A.; Bouscambert-Duchamp, M.; Donati, F.; Le Hingrat, Q.; et al. Clinical and Virological Data of the First Cases of COVID-19 in Europe: A Case Series. Lancet Infect. Dis. 2020, 20, 697–706. [Google Scholar] [CrossRef]
  29. Ibrahim, S.; Al-Saryi, N.; Al-Kadmy, I.M.S.; Aziz, S.N. Multidrug-Resistant Acinetobacter baumannii as an Emerging Concern in Hospitals. Mol. Biol. Rep. 2021, 48, 6987–6998. [Google Scholar] [CrossRef]
  30. Antimicrobial Resistance Collaborators. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. Lancet 2022, 399, 629–655. [Google Scholar] [CrossRef]
  31. Lau, M.Y.; Ponnampalavanar, S.; Chong, C.W.; Dwiyanto, J.; Lee, Y.Q.; Woon, J.J.; Kong, Z.X.; Jasni, A.S.; Lee, M.C.C.; Obaidellah, U.H.; et al. The Characterisation of Carbapenem-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Teaching Hospital in Malaysia. Antibiotics 2024, 13, 1107. [Google Scholar] [CrossRef]
  32. Yu, K.; Zeng, W.; Xu, Y.; Liao, W.; Xu, W.; Zhou, T.; Cao, J.; Chen, L. Bloodstream Infections Caused by ST2 Acinetobacter baumannii: Risk F actors, Antibiotic Regimens, and Virulence over 6 Years Period in China. Antimicrob. Resist. Infect. Control 2021, 10, 16. [Google Scholar] [CrossRef]
  33. Pustijanac, E.; Hrenović, J.; Vranić-Ladavac, M.; Močenić, M.; Karčić, N.; Stefanović, L.L.; Hrstić, I.; Lončarić, J.; Musić, M.Š.; Drčelić, M.; et al. Dissemination of Clinical Acinetobacter baumannii Isolate to Hospital Environment during the COVID-19 Pandemic. Pathogens 2023, 12, 410. [Google Scholar] [CrossRef]
  34. Bedenić, B.; Bratić, V.; Mihaljević, S.; Lukić, A.; Vidović, K.; Reiner, K.; Schöenthaler, S.; Barišić, I.; Zarfel, G.; Grisold, A. Multidrug-Resistant Bacteria in a COVID-19 Hospital in Zagreb. Pathogens 2023, 12, 117. [Google Scholar] [CrossRef]
  35. Zingg, S.; Kuster, S.; von Rotz, M.; Portmann, A.; Egli, A.; Seth-Smith, H.M.; Schlaepfer, P.; Goldenberger, D.; Bassetti, S.; Marsch, S.; et al. Outbreak with OXA-23-producing Acinetobacter baumannii in a COVID-19 ICU cohort: Unraveling routes of transmission. Antimicrob. Resist. Infect. Control 2024, 13, 127. [Google Scholar] [CrossRef]
  36. Cureño-Díaz, M.A.; Plascencia-Nieto, E.S.; Loyola-Cruz, M.Á.; Cruz-Cruz, C.; Nolasco-Rojas, A.E.; Durán-Manuel, E.M.; Ibáñez-Cervantes, G.; Gómez-Zamora, E.; Tamayo-Ordóñez, M.C.; Tamayo-Ordóñez, Y.d.J.; et al. Gram-Negative ESKAPE Bacteria Surveillance in COVID-19 Pandemic Exposes High-Risk Sequence Types of Acinetobacter baumannii MDR in a Tertiary Care Hospital. Pathogens 2024, 13, 50. [Google Scholar] [CrossRef]
Pathogens 14 00961 g001
Figure 1. Study design and sampling scheme from patients and hospital environment.
Figure 1. Study design and sampling scheme from patients and hospital environment.
Pathogens 14 00961 g001
Pathogens 14 00961 g002
Figure 2. Neighbor-joining phylogenetic tree of A. baumannii clinical isolates and reference sequences from the PubMLST database. Colored clades: red (ST2), purple (ST78), and yellow (ST19). Blue: study isolates; Black: PubMLST database; Green: GenBank reference.
Figure 2. Neighbor-joining phylogenetic tree of A. baumannii clinical isolates and reference sequences from the PubMLST database. Colored clades: red (ST2), purple (ST78), and yellow (ST19). Blue: study isolates; Black: PubMLST database; Green: GenBank reference.
Pathogens 14 00961 g002
Pathogens 14 00961 g003
Figure 3. Distribution of A. baumannii ST isolated from patients and environmental samples.
Figure 3. Distribution of A. baumannii ST isolated from patients and environmental samples.
Pathogens 14 00961 g003
Table 1. Comparative analysis of A. baumannii ST2 isolates according to the cgMLST scheme.
Table 1. Comparative analysis of A. baumannii ST2 isolates according to the cgMLST scheme.
Sample IDClosest cgSTMismatches, nLoci Matched, %
6-531-2-III_S517462498.9
108-2-III_S9174611094.8
50-2-III_S11174611595.6
61-II_S53174611594.6
72-III_S10174611794.5
42-III_S7174612194.3
26-III_S22174612994.0
55-II_S52174613893.5
19-II_S16174615692.7
27-III_S34174617192.0
346-II_S33174618691.3
63-II_S54174620290.5
44-2-III_S6174621190.1
4-II_S19174622289.6
69-II_S57174622889.3
198-II_S29174623289.1
100-II_S24174625887.9
104-II_S261746, 11,00646178.4
188-II_S28174658372.7
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Smirnova, S.S.; Avdyunin, D.D.; Holmanskikh, M.V.; Stagilskaya, Y.S.; Zhuikov, N.N.; Itani, T.M. Genetic Characteristics of Acinetobacter baumannii Isolates Circulating in an Intensive Care Unit of an Infectious Diseases Hospital During the COVID-19 Pandemic. Pathogens 2025, 14, 961. https://doi.org/10.3390/pathogens14100961

AMA Style

Smirnova SS, Avdyunin DD, Holmanskikh MV, Stagilskaya YS, Zhuikov NN, Itani TM. Genetic Characteristics of Acinetobacter baumannii Isolates Circulating in an Intensive Care Unit of an Infectious Diseases Hospital During the COVID-19 Pandemic. Pathogens. 2025; 14(10):961. https://doi.org/10.3390/pathogens14100961

Chicago/Turabian Style

Smirnova, Svetlana S., Dmitry D. Avdyunin, Marina V. Holmanskikh, Yulia S. Stagilskaya, Nikolai N. Zhuikov, and Tarek M. Itani. 2025. "Genetic Characteristics of Acinetobacter baumannii Isolates Circulating in an Intensive Care Unit of an Infectious Diseases Hospital During the COVID-19 Pandemic" Pathogens 14, no. 10: 961. https://doi.org/10.3390/pathogens14100961

APA Style

Smirnova, S. S., Avdyunin, D. D., Holmanskikh, M. V., Stagilskaya, Y. S., Zhuikov, N. N., & Itani, T. M. (2025). Genetic Characteristics of Acinetobacter baumannii Isolates Circulating in an Intensive Care Unit of an Infectious Diseases Hospital During the COVID-19 Pandemic. Pathogens, 14(10), 961. https://doi.org/10.3390/pathogens14100961

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop